The bill directs the President to implement a National Biotechnology Initiative to advance national security, economic productivity, and competitiveness by coordinating federal biotechnology activities. It requires the Executive Office of the President to host a National Biotechnology Coordination Office and an interagency committee to bring agency programs, data resources, regulatory pathways, workforce development, and commercialization efforts into a unified framework.
This matters because the measure centralizes federal biotech policymaking in the EOP rather than leaving coordination to scattered agencies. If enacted, it changes how agencies plan and fund biotech R&D, how biological data are curated and shared, and how products developed with biotechnology move through regulatory pathways and into markets—while also building in biosecurity, workforce, and international engagement priorities.
At a Glance
What It Does
Creates a cross‑government National Biotechnology Initiative with a coordination office in the Executive Office of the President and an interagency committee to align activities across participating departments. It directs development of a public federal biotech website, an annual reporting regime, a periodic national strategy, and targeted activity areas including data, regulatory streamlining, commercialization, biosafety, and workforce development.
Who It Affects
Federal science, defense, agriculture, health, trade, and regulatory agencies; research universities and national labs; biotech companies and biomanufacturers; startups and testbeds; and international trading and regulatory partners engaged with U.S. biotech products and data.
Why It Matters
By combining policy, coordination, and a visible public portal, the Initiative aims to reduce duplicative federal efforts, create clearer regulatory paths for biotechnology products, and treat biological data as strategic infrastructure—moves that could speed commercialization but also raise policy questions about oversight, security, and resource allocation.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill charges the President, acting through the Executive Office of the President, with implementing a National Biotechnology Initiative to better align federal activities that touch biotechnology. To operationalize that charge it requires creation of a National Biotechnology Coordination Office in the EOP and designation of an Interagency Committee made up of Assistant Secretary–level representatives from participating departments.
Participating agencies are explicitly enumerated (Agriculture, Commerce, Defense, Energy, HHS, DHS, Interior, State, EPA, NASA, NSF, ODNI, USTR) with room for additional agencies the Director deems appropriate.
The Director of the Coordination Office is the President’s principal biotechnology advisor and is empowered to convene the interagency committee, advise OMB on budget alignment, coordinate regulatory pathways, hire staff, and leverage services across agencies. The Office’s functions are broad: planning and coordination; national‑security assessments and counterintelligence gap‑filling; R&D coordination and cross‑agency solicitations; stewardship and standardization of biological data and databases; strategies to accelerate private‑sector translation and national testbeds; regulatory streamlining plans and interagency agreements; biosafety and biosecurity frameworks; workforce and bioliteracy initiatives; and international regulatory and commercial diplomacy.The bill sets concrete deliverables and timing: an Interagency Committee and Office established and a Director appointed within statutory deadlines; a single coordinated public federal biotech website with a dashboard and a digital portal for consolidated submissions; an annual report to Congress; and a comprehensive national strategy to be produced within two years and updated at least every five years.
It also builds accountability through Comptroller General reviews and directs OMB to intervene and negotiate interagency regulatory pathways if the Office and Interagency Committee cannot agree. Administrative support is assigned to NSF, which is authorized funding for several fiscal years to stand up and run the Office and provide staff and infrastructure.The statute requires each participating agency to name senior leads, to align agency programs with the national strategy, and to carry out a menu of activities (data curation, joint solicitations, testbeds, regulatory trials, biosafety planning, workforce and education programs, and international engagement).
The Office is designed to last two decades before winding down into an executive secretariat, with provisions for transferring functions and preserving a coordination capability after the sunset period.
The Five Things You Need to Know
The bill requires establishment of a National Biotechnology Coordination Office in the Executive Office of the President and the appointment of its Director within 180 days of enactment.
NSF must provide administrative support and the bill authorizes appropriations to NSF of $22M for FY2026, $35M for FY2027, and $25M each for FY2028–FY2030 to stand up and run the Office.
Congressional reporting and public transparency: a single coordinated federal biotech website must be published (deadline 540 days) that includes a dashboard, plain‑language materials, a repository of interagency regulatory agreements, and a digital portal to submit a single application shared across agencies.
If the Office and Interagency Committee cannot agree on a clear regulatory pathway for a product type, the Director of the Office of Management and Budget must identify gaps and negotiate an interagency agreement and oversee rulemaking or guidance changes to implement it.
The Office is designed to wind down 20 years after enactment and includes a schedule for Comptroller General reviews beginning at year 3 (with an initial briefing at 3.5 years and a report at year 4), repeated every 5 years until wind‑down.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Creates the National Biotechnology Initiative and names participants
Section 3 is the authorization hook: it requires the President to implement an Initiative to advance national security, economic productivity, and competitiveness through coordinated federal biotech activity. It lists participating agencies by name (Agriculture, Commerce, Defense, Energy, HHS, DHS, Interior, State, EPA, NASA, NSF, ODNI, USTR) and allows the Director to add others. That enumeration matters because it defines the core functions and perspectives the Initiative must unify—civilian research, defense, trade, regulatory, and environmental stewardship.
Establishes an Interagency Committee with senior agency liaisons
Section 4(a) requires the President to designate an interagency committee within 180 days and specifies membership at the Assistant Secretary level. The Committee must coordinate planning and ensure each participating agency supports Initiative activities. Practical implication: agencies must name senior leads and create internal lines of authority to meet interagency commitments; the statute also sets rules for co‑chairs, terms, and quorum, which shape governance and rotating leadership.
Establishes a National Biotechnology Coordination Office in the EOP and a Director
This subsection places a permanent coordination function in the Executive Office of the President and enumerates the Director’s advisory and operational authorities, including advising OMB on budget alignment, convening the Committee, coordinating regulatory approaches, hiring staff, entering into contracts, and accepting personnel and services from other agencies. Housing the office in EOP concentrates cross‑cutting authority and gives the Director leverage to push for interagency alignment, but it also centralizes influence outside the standard agency rulemaking tracks.
Office functions: planning, national security, R&D, data, commercialization, regulation, biosafety, workforce, and international engagement
The Office’s functional list is intentionally wide: it covers strategic planning, gap assessments, fellowship rotations, national strategy development, and operational priorities such as standardizing biological data and deploying interoperable datasets for AI. It also directs work on product commercialization (testbeds, scale‑up), regulatory streamlining (interagency agreements and public plans), biosafety/biosecurity frameworks, and workforce and bioliteracy initiatives. Each function creates follow‑on expectations for agencies and stakeholders to produce standards, shared infrastructure, and coordinated programs.
Requires a single coordinated federal biotechnology website and digital submission portal
The bill sets a 540‑day deadline for a public website that centralizes federal biotech activities—dashboard, funding opportunities, plain‑language materials, a Q&A mechanism, interagency agreements and decision documents, and a digital portal allowing consolidated submissions to multiple agencies. For industry and researchers, that portal is a practical change: it aims to reduce the friction of multi‑agency filings but implies substantial backend data‑sharing and interoperability work among agencies.
Annual reporting and a comprehensive national biotechnology strategy
Section 4(d) requires annual reports to specified Congressional committees with an inventory of activities and spending and planned actions. Section 4(e) requires a comprehensive national strategy within two years and at least every five years thereafter; the strategy must include action plans, a 5‑year budget estimate for unmet priorities, an inventory and assessment of biological data assets, competitiveness analysis versus peer countries, and recommendations for legislative or administrative fixes. Together those provisions create recurring strategic and fiscal accountability points.
Administrative support, OMB conflict role, wind‑down, and specific agency obligations
NSF is directed to provide administrative support and staffing for the Office and is statutorily authorized specific appropriations for FY2026–FY2030. If the Office and Interagency Committee cannot reach timely agreement on regulatory pathways, OMB must step in to negotiate and recommend rulemaking. The Office will wind down after 20 years and transition into an executive secretariat with transfers of authorities as appropriate. Section 6 compels participating agencies to name Assistant Secretary‑level leads and execute a long checklist of activities—from joint solicitations and data curation to regulatory trials, biosafety planning, testbeds, and international engagement—creating concrete duties at the agency level.
This bill is one of many.
Codify tracks hundreds of bills on Science across all five countries.
Explore Science in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Academic researchers and national labs — clearer data standards, sustained support for biological databases, and coordinated joint solicitations that can unlock interdisciplinary funding and shared computational tools.
- Biotechnology companies and startups — access to a digital portal, testbeds, coordinated regulatory pathways, and commercialization incentives designed to reduce time‑to‑market and scale manufacturing.
- Regulators and agencies — a central forum and interagency agreements that can clarify jurisdictional overlaps and create predictable decision timelines.
- Workforce and education programs — federal coordination on training, fellowships, and curricular support that can expand the domestic pipeline of biotech talent, including reskilling and veteran programs.
- International partners and exporters — coordinated commercial diplomacy and data‑sharing frameworks that aim to harmonize standards and open markets for U.S. biotech products.
Who Bears the Cost
- National Science Foundation — assigned administrative responsibility and staffing obligations plus the initial appropriations and overhead for running the Office, which shifts program management workload to NSF.
- Participating federal agencies — required to designate senior leads and to deliver on extensive mission‑specific activities (data curation, regulatory trials, testbeds, workforce programs) that may require internal reorganization and new funding.
- Office of Management and Budget — tasked with resolving regulatory impasses and potentially overseeing consequential interagency agreements and rulemaking recommendations.
- Taxpayers and appropriators — the bill authorizes multi‑year funding and anticipates new interagency programs and infrastructure investments that will require sustained appropriations beyond authorization years.
- Small and midsize firms — while beneficiaries of clearer pathways, they may face upfront compliance and integration costs to meet new data standards or participate in interagency testbeds and regulatory trials.
Key Issues
The Core Tension
The central dilemma: accelerate U.S. biotech innovation and commercialization through centralized coordination, streamlined regulation, and open data, while preserving rigorous biosafety, biosecurity, and privacy safeguards—and doing so without shifting unfunded burdens to agencies or allowing political priorities to trump technical regulatory judgment.
The bill centralizes coordination in the Executive Office of the President and gives the Director broad authorities to shape budgets, regulatory pathways, and data standards. That concentration can speed interagency work but may also compress agency discretion and technical review processes; agencies with deep statutory expertise could find political or administrative priorities at odds with technical risk assessments.
The statutory requirement that OMB step in when the Office and Interagency Committee cannot agree creates a backstop, but it raises the prospect that resolution could be driven by budgetary or political considerations rather than purely technical criteria.
Regulatory streamlining is explicit: the statute directs easing regulation for well‑understood product types and short‑term regulatory trials to establish or update pathways. The tension here is clear—speeding commercialization reduces friction for industry but increases the risk that nuanced biosafety, environmental, or long‑term epidemiological considerations receive less scrutiny.
Likewise, the bill treats biological data as strategic infrastructure and pushes for interoperability and open datasets; balancing openness, commercial confidentiality, and national security (and the privacy of human genetic data) will be technically and politically fraught. Finally, the funding authorization and twenty‑year wind‑down create planning uncertainty: agencies must implement near‑term obligations with only a multi‑year authorization that may or may not cover long‑term maintenance costs, and the scheduled transition at year 20 may complicate long‑lived infrastructure decisions.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.